## Distinguishing MCAD from LCAD Deficiency ### Pathophysiology of Fatty Acid Oxidation Defects Both MCAD and LCAD are disorders of β-oxidation, but they impair oxidation of different chain lengths, leading to distinct metabolite accumulation patterns and clinical presentations. ### Key Biochemical Difference **High-Yield:** The cardinal discriminator is the **acylcarnitine profile on tandem mass spectrometry (MS/MS)**: | Feature | MCAD Deficiency | LCAD Deficiency | |---------|-----------------|------------------| | **Substrate blocked** | Medium-chain (C6–C10) fatty acids | Long-chain (C12–C18) fatty acids | | **Elevated acylcarnitines** | C6, C8, C10 (especially C8) | C12, C14, C16, C18 | | **Urine organic acids** | Hexanoate, octanoate, decanoate | Elevated dicarboxylic acids (but longer chain) | | **Primary presentation** | Hypoketotic hypoglycemia + encephalopathy | Cardiomyopathy, skeletal myopathy, lipid storage | | **Age of onset** | 3 months–2 years (often after viral illness) | Neonatal or early infancy | **Key Point:** MS/MS acylcarnitine profiling is the gold standard for diagnosis and allows precise differentiation by chain length of accumulated acyl-CoA species. ### Clinical Context MCAD is the most common fatty acid oxidation disorder in Caucasians (1:6,000–1:10,000); LCAD is rarer but more severe, with cardiac involvement being a hallmark feature. **Clinical Pearl:** A child presenting with **hypoketotic hypoglycemia + normal ketones during fasting** suggests MCAD, whereas **progressive cardiomyopathy + lipid storage in muscle** points to LCAD. ### Why MS/MS Acylcarnitine Profile is Diagnostic The specific pattern of elevated acylcarnitines reflects the exact enzymatic block: - **MCAD block** → C6–C10 accumulate (cannot be oxidized further) - **LCAD block** → C12–C18 accumulate (cannot enter the β-oxidation spiral) This is measured directly and unambiguously in newborn screening and diagnostic panels.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.